Introduction
Conditionally replicating viruses (CRVs) offer the promise of a powerful weapon in our clinical arsenal against cancer.
1,2 Such viruses are designed to be capable of selectively replicating in tumour cells, leading to their destruction, while sparing normal cells. Perhaps most appealing is their inherent potential for further in vivo amplification of tumour-selective virus and spread through tumours. In the ideal situation, they will be both self-propagating and self-limiting. However, in reality, the current generation of CRVs in the clinic may have only limited potency against tumours.
Superseding generations of CRVs have been designed with increased efficacy in mind but these, in turn, heighten concerns over safety. Minimizing the possibility of unchecked CRV spread in patients or the environment should be an ultimate safety goal.
The Gene Therapy Advisory Committee (GTAC) is the UK government body that considers the acceptability of gene therapy clinical research proposals based on scientific, safety and ethical considerations. CRVs also have medicinal product, GMO, public health and environment considerations. These are within the remits of the UK's Medicines Control Agency, Health and Safety Executive, Department of Health and Department of Environment' (DEFRA), respectively. On 12 March 2002, GTAC hosted a forum in London to consider emerging trends in CRV development and the benefits and risks associated with their clinical application. Those discussions are presented here. While the forum focused mainly on adenoviral vectors, the issues are broadly pertinent to other CRVs.
Discussion
What do we need and want from CRV's?
The ultimate aspiration in CRV development is to generate oncolytic agents that can target and destroy both tumour masses and disseminated tumour cells by systemic administration, but that are non-toxic to normal tissue. A satisfactory balance must be struck between the safety and efficacy of CRVs, a task as yet not achieved. Clinical experience thus far has indicated that the first generations of CRVs are safe, but of limited efficacy. [3] [4] [5] It has bee suggested that many safety issues for CRVs will only be relevant when a truly efficient system is established that is capable of aggressively destroying tumours. One of the most significant impediments for CRVs, or indeed any cancer therapy, is that many tumour masses are made up of a heterogeneous mixture of tissue, including vasculature and fibrous material, which is not directly subject to CRV oncolytic activity. Such tissue may also act as a 'firewall' to CRV spread within the tumour.
To their advantage, the antitumour activity of CRVs may be augmented by the 'Bystander Effect'. 6 This is a well-documented phenomenon where antitumour activity in transduced tumour cells seems to induce further localized responses against both infected and uninfected tumour tissue. It is also believed that chemotherapy and perhaps radiotherapy may synergize with the oncolytic effects of CRVs, possibly by non-specific disruption of tumour masses. 7 Thus, the efficacy of CRVs may be further enhanced by manipulation of genes which modulate immune system response or in combination with radio-or chemotherapy. In that sense and because of the limited treatment options available to some cancer patients, it is anticipated that the next generation of CRVs will be more genetically modified than their predecessors, more sophisticated in their action and more potent in their anticancer activity.
Design features of CRVs
There are two major approaches to the generation of CRVs.
1,2 One is to eliminate viral genes which are dispensable in tumour cells and the second is to replace viral promoters with tumour-specific promoters to express viral gene products required for replication or progeny production. Alteration of viral tropism by modification of coat proteins is an additional possibility.
In the case of adenovirus, wild type has previously been used to infect tumour cells, albeit non-specifically. 8 This raises an interesting question about CRVs. Does the virus truly target cancer cells or do cancer cells support differential replication of the virus, by altered cell growth rates for example? In the latter case, the safety issues may be greater.
The first generation of adenoviral CRVs were designed to be tumour cell selective in their killing action, based on the knowledge of viral life cycle and tumour biology. ONXY-015, or dl1520, is deleted in the E1B gene encoding a 55 kDa protein, the major function of which appears to involve interaction with p53. 9 The original theory was that only in tumour cells, where p53 status is generally disrupted, could virus cause cell death and produce further tumour cell infection. However, other adenoviral proteins may be involved in p53 interaction and the E1B 55 kDa protein may have a number of other roles, such as in viral mRNA translation, so that the original premise for tumour selectively may have been based on an oversimplified model. 1, 2, 10 In this particular case, selection of mutants in E1B 55 kDa that lose the ability to bind p53 but not other functions would be valuable. Newer deletion variants of adenovirus may well be more potent and specific to tumour cells.
A different oncolytic viral system is based on a mutant of Herpes Simplex Virus (HSV), known as HSV1716. 11 Here, deletion of a viral gene RL1 eliminates expression of ICP34.5, a protein known to interact with proliferating cell nuclear antigen (PCNA). In normal cells, loss of ICP34.5 results in a virus with a severely impaired ability to replicate. However, in may tumour cells PCNA is upregulated and viral replication is supported so that selective oncolysis can occur.
There are numerous variants of these and other viruses, which confer at least some level of tumourselective growth and oncolytic potential, all at various stages of development. Further deletion of viral genes that interact with the host cell replication machinery or which act as a shield to the immune system, expression of viral replication genes under the control or tumourselective promoters, engineering or viral message stability signals which support growth only in tumour cells, or expression of immunostimulatory, pro-drug converting, or secreted pro-apoptotic proteins or toxins are all being investigated. One ultimate design aim would be to produce a CRV where replication could be restricted to tumour cells by both temporal and spatial control, perhaps involving inducible regulation via small molecules, radiation or some other externally controllable medium. 12 Viruses that are simply attenuated, like ONXY-015 or HSV1716, represent less perceived risk than viruses containing exogenous genes. This differential in risk would be reflected in the level of pre-clinical data supporting a research proposal. Given that many CRVs will have no safety track record, the incorporation of suicide genes into vectors should be considered. 6 HSVderived vectors contain the thymidine kinase gene, allowing gancyclovir to be administered where viral spread could become a problem. It is recognized that imposing design constraints at such an early stage in the development of this field may hinder clinical progress. However, with new viruses where there is no safety track record in humans, which are potentially more virulent that parental strains and which contain a therapeutic payload that could be toxic in certain circumstances, the incorporation of suicide genes should be explored. When a suicide gene is employed, it would be important to assay its stability within the vector, particularly as the virus goes through replicative cycles in tumour cells. As mentioned, an alternative approach to limit the potential risks of CRVs to the patient (and indeed the environment) relies on the use of small molecule control of viral action, such as with rapamycin or rapamycin analogues. 12 In new generations of CRVs, the incorporation of therapeutic genes may be a pre-requisite for these vectors to be effective, given the heterogeneous nature of tumours and how cancer cells may be shielded from the CRV. Strategies that include the expression of secreted molecules capable of inducing death in disseminating tumour metastases are being considered. Like suicide genes, the stability of inserted transgenes as the CRV goes through replicative cycles in tumour cells should be examined.
The potential for generating replicating non-selective viruses, essentially wild type in character, during the manufacture or clinical application of CRVs should be investigated. Such replication non-selective viruses may possess a replicative advantage over the CRV population and, with multiple rounds of infection and propagation, could predominant and cause damage to normal tissues.
Tumour-selective promoters and altered tropism
Tumour-'specific' (or perhaps more appropriately tumour-'selective' promoters) and tissue-specific promoters which are restricted to tumours are being actively explored. However, while promoters may show the desired properties within plasmid vectors, they may become promiscuous in the context of a viral genome. 13 In addition, baseline promoter 'leakiness' may be a significant problem. Minimal levels of viral gene products may be sufficient to abrogate replication selectively. Many promoters are likely to show' differential' rather than specific activity in the tumour tissue. When any new promoter is being considered for use in either a CRV or indeed to drive expression of any transgene which may have lethal consequence in both tumour and normal cells (such as a pro-drug-activating enzyme), considerable evidence indicating the specificity of its control would be warranted. An additional consideration in the use of tissue-selective promoters rests on species specificity of the pre-clinical data. A promoter with specific activity in human cells may not function in animals cells and would therefore limit the persuasiveness of pre-clinical animal model data.
CRVs are also being designed with altered tropism, either by genetic or biochemical modification of capsid proteins or by use of tissue-specific promoters driving expression of viral capsid genes. 1 In these cases, altered tropism of the virus could result in the infection of both the desired cell type and of new or unpredicted cell types. In this scenario, it is possible that the CRV would cause a new type of pathology. There is an important distinction to be made between converting viral tropism to new cell types and restricting viral replication to a subset of cells of the parental virus, particularly where systemic delivery is being considered. There is also evidence that adenovirus, for example, may be able to bind cells somewhat non-specifically, for example via heparan sulphate-glycosaminoglycan receptors, particularly at high titres.
14 Where normal tissue serves as a 'sink' for viral infection, it is possible that viral infectivity and behaviour within those normal tissues will be altered. Undoubtedly, as CRVs become more sophisticated and, presumably, more effective at targeting cancer cells, the analysis of the risks both to the patient and the environment will become more complicated.
Pre-clinical tests for CRVs
A vital question in pre-clinical research is how do CRVs compare in terms of safety and potency with their wildtype counterparts? A second consideration for both pre-clinical studies and clinical proposals is that increasing viral input titres may decrease target selectivity, for
Conditionally replicating viruses in cancer therapy JB Connolly example, via non-specific receptor binding. Characterization of CRVs in appropriate pre-clinical animal models remains a significant problem, particularly in the case of adenovirus. Ideally, pre-clinical animal studies should allow assessments of toxicity and not simply modeling of tumours, the latter being the case in mouse xenograft experiments. True toxicology of CRVs can only be determined in a host where replication is permitted. This issue becomes particularly germane when one considers clinical scenarios where an intratumoural site of injection is missed and virus is inadvertently given systemically via a major blood vessels. In general, mouse cells are poor at supporting adenoviral growth, although some permissive mouse cell lines have been identified. 15, 16 It would be useful to have mouse models where the selectively of CRV replication can be established and the true toxicity of a replicating agent more accurately gauged. In their absence, it is worth noting that cotton rats and pigs support adenoviral replication. [15] [16] [17] [18] Recent advances in imaging technology offer sophisticated approaches to complement more established PCR-based biodistribution studies in animal models. Several techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning have been used to visualize viral delivery and gene expression in living animals. [19] [20] [21] In particular, oncolytic viruses such as HSV, expressing the thymidine kinase gene, can be imaged using (124)-5-iodo-2 0 -fluoro-1-betad-arabinofuranosyl-uracil (FIAU). These imaging techniques will undoubtedly become increasingly important in regulatory assessments of the proliferation and biodistribution of CRVs in animal models.
Clinical encounters with CRVs
Because CRVs are replicating agents, the input titer will not necessarily correlate with the viral titre in patient tissues. However, to date, clinical experience with CRVs has revealed only limited viral replication and spread within tumour masses.
2-5 Intra-tumoural 'radial' injection that physically spreads viral material within the tumour has been used to some effect. Although there has been some evidence of viral tumour killing, cell escape at the tumour margin has been commonly observed.
The presence of neutralizing antibodies against the parental virus may reduce the ability of the CRV to evade the host immune system and attack tumour cells.
1,2 Data are limited, but many adults seem to carry subgroups of parental viruses, especially in the case of adenoviral and HSV CRVs. Some serotypes of viruses also show persistence in the kidney. Further, the initial exposure to the CRV could induce host immune responses to the virus and reduce the potency of repeated CRV administration. Limited clinical experience with both HSV1716 and ONYX-015 suggests that the presence of antibodies against the parental virus does not necessarily correlate with the anti-tumour effects of the CRV. 4 Indeed, it has been argued that the presence of such antibodies could in fact augment the anti-tumour effect of the CRV. With lysis of cancer cells and further release of CRV, the host may mount an immune response against CRV-infected tumour cells. Unlike antibody responses, little is known about cell-mediated host immune responses to adenovirus and other CRVs, an area worth exploring further.
Where a new CRV is proposed for a research trail, close clinical monitoring of the first sub-group of patients would be required. Patient monitoring should take into account the probability of 'secondary waves' of replicating virus. For instance, in the case of ONXY-015 intravenous studies, an additional spike in the number of viral genomes was observed between 48 and 72 h postinjection. 2 In the near future, it may be practicable to assess qualitatively and quantitatively CRV delivery, gene expression and replication in patients using highresolution imaging techniques. 19 'Viral shedding' is an important issue. 22, 23 The potential for cyclical shedding of CRV poses different considerations than for non-replicating gene therapy viruses. It may be necessary to carry out more stringent examination of shedding in initial patient sub-groups to determine the risk of transmission. However, in general, it has been suggested that there should not be an absolute requirement to isolate patients. Rather, CRVtreated patients could be provided with instructions similar to those who have received large doses of radioisotopes. In the case of CRV containing only deletions, it is worth remembering that the wild-type counterparts may be extremely common among the population.
Some regulatory bodies, such as GTAC, have issued special recommendations on patient monitoring for all trials involving adenoviral vectors. 24 These should also be consulted when the use of conditionally replicating adenovirus is being proposed. In the past, it has also been requested that investigators report back to GTAC on a patient-by-patient basis in some trials involving CRVs.
Finally, it is worth considering research site issues. The perceptions of research, nursing and general hospital staff to these viruses may not always be based on pertinent issues. It is worth educating staff on any risks from the study agent prior to initiating clinical research. This should serve to allay any misguided concerns over the CRV and to increase the understanding for standard operating procedures (SOPs). SOPs should be written in advance of research trials and freely available to staff. For each research trial, it is important to have a clinical microbiologist on hand who understands the protocol, is familiar with the study agent, can advise on the SOPs, can explain microbiological issues to the staff and from whom advice can be sought in the event of mishap. It is worth reflecting on the fact that may pathogens in hospital patients are considerably more dangerous that the present generation of gene therapy vectors and CRVs. The clinical microbiologist should be able to frame any risks from the vector in the appropriate context.
Conclusions
The development of CRVs with tumour-selective promoters, engineering of inducible viral gene expression and replication systems, incorporation of transgenes encoding pro-drug-activating enzymes, toxins and immunostimulatory proteins, or further genomic rearrangements to confer increased tumour-selective properties on CRVs are all being pursued with vigour. However, for adenoviral vectors, cogent pre-clinical animal models, which support the replication of the CRV in host cells
Conditionally replicating viruses in cancer therapy
JB Connolly and that can be used to assess host toxicological and immunological response to these viruses, still do not exist. Nonetheless, to date, the use of CRVs, such as ONYX-015 or HSV1716, in patients has proved safe, albeit of limited efficacy. Given the potential for viral non-selectively in and toxicity to non-target organs, proposals to administer these agents via intra-venous or -arterial delivery will continue to require considerable pre-clinical and clinical justification, Although this field is maturing, it is still too early for GTAC to provide prescriptive advice to researchers proposing to use CRVs in cancer patients. Instead, researchers are encouraged to contact the secretariat of their national gene therapy supervisory body for pre-proposal discussion prior to any formal submission.
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